These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 32050434)

  • 21. Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients.
    Balandín B; Ballesteros D; Pintado V; Soriano-Cuesta C; Cid-Tovar I; Sancho-González M; Pérez-Pedrero MJ; Chicot M; Asensio-Martín MJ; Silva JA; de Luna RR; Gesso CM; Rodríguez-Serrano DA; Martínez-Sagasti F; Royuela A
    Int J Antimicrob Agents; 2022 Mar; 59(3):106536. PubMed ID: 35091054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the clinical application of ceftazidime-avibactam in China.
    Wang Q; Xu P; Zhou Y
    J Infect Public Health; 2022 Apr; 15(4):455-459. PubMed ID: 35216921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Shields RK; Clancy CJ; Pasculle AW; Press EG; Haidar G; Hao B; Chen L; Kreiswirth BN; Nguyen MH
    J Clin Microbiol; 2018 Feb; 56(2):. PubMed ID: 29167294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Ceftazidime-Avibactam in Gram-Negative Nosocomial Pneumonia: A Real-World Study in India.
    Gupta N; Saseedharan S; Paliwal Y
    Cureus; 2024 Feb; 16(2):e54443. PubMed ID: 38510907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.
    Sousa A; Pérez-Rodríguez MT; Soto A; Rodríguez L; Pérez-Landeiro A; Martínez-Lamas L; Nodar A; Crespo M
    J Antimicrob Chemother; 2018 Nov; 73(11):3170-3175. PubMed ID: 30099490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
    Flamm RK; Farrell DJ; Sader HS; Jones RN
    J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the
    Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
    Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
    J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated With Ceftazidime-Avibactam: A Single-Center Observational Study.
    Rathish B; Wilson A; Warrier A; Prakash S; Babu R; Joy S
    Cureus; 2021 Feb; 13(2):e13081. PubMed ID: 33680621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
    Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
    mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by
    Daikos GL; da Cunha CA; Rossolini GM; Stone GG; Baillon-Plot N; Tawadrous M; Irani P
    Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572708
    [No Abstract]   [Full Text] [Related]  

  • 34.
    Viaggi V; Pini B; Tonolo S; Luzzaro F; Principe L
    J Chemother; 2019 Jul; 31(4):195-201. PubMed ID: 31130090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.
    Sader HS; Castanheira M; Flamm RK; Huband MD; Jones RN
    Surg Infect (Larchmt); 2016 Aug; 17(4):473-8. PubMed ID: 27104633
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario.
    Swaminathan S; Routray A; Mane A
    Cureus; 2022 Aug; 14(8):e28283. PubMed ID: 36072213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
    van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
    Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.
    Sy SKB; Zhuang L; Sy S; Derendorf H
    Clin Pharmacokinet; 2019 May; 58(5):545-564. PubMed ID: 30097887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).
    Sader HS; Huband MD; Duncan LR; Flamm RK
    Pediatr Infect Dis J; 2018 Jun; 37(6):549-554. PubMed ID: 29206750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.